** Shares of drugmaker Gilead Sciences GILD.O climb 4.1% to $117.28 premarket
** Company says it resolved patent litigations with Indian drugmakers Lupin, Cipla and Laurus Labs, which had filed a marketing application for generic versions of GILD's HIV drug Biktarvy
** GILD says no generic entry of certain versions of the drug is expected prior to April 1, 2036 in the United States
** Up to last close, GILD shares up 22% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))